<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">19020413</PMID>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1473-5849</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural pharmacology</Title>
                <ISOAbbreviation>Behav Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>786-95</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/FBP.0b013e32831c3b2b</ELocationID>
            <Abstract>
                <AbstractText>Prepulse inhibition (PPI) of the startle reflex is an operational measure of sensorimotor gating that is deficient in several brain disorders and is disrupted in rats by dopamine (DA) agonists. Robust heritable strain differences are observed between Sprague-Dawley (SD) and Long-Evans (LE) strains in sensitivity to the PPI-disruptive effects of DA agonists associated with differential gene expression in the nucleus accumbens. Here, we compared the contribution of D2 versus D3 receptors with this heritable difference, using the D3-preferential agonist (pramipexole), the mixed D3/D2 agonist (quinpirole), the mixed D1/D2-like agonist (apomorphine), and the preferential D2 antagonist (L741,626). All DA agonists disrupted PPI in SD and LE rats. Greater sensitivity for this effect was evident with apomorphine and quinpirole in SD than LE rats, but not with pramipexole. The selective D2 antagonist L741,626 preferentially reversed apomorphine-induced PPI deficits at a dose that did not alter pramipexole-induced PPI deficits. We conclude that the heritable pattern of greater PPI 'disruptability' by DA agonists in SD versus LE rats reflects differences in D2 but not D3 receptor-associated mechanisms.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, UCSD School of Medicine, La Jolla, California 92093-0804, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Wei-li</ForeName>
                    <Initials>WL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breier</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swerdlow</LastName>
                    <ForeName>Neal R</ForeName>
                    <Initials>NR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 MH068366</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH068366-04</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MH68366</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Behav Pharmacol</MedlineTA>
            <NlmUniqueID>9013016</NlmUniqueID>
            <ISSNLinking>0955-8810</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>81226-60-0</RegistryNumber>
                <NameOfSubstance UI="C104750">3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009714" MajorTopicYN="N">Nucleus Accumbens</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName>
                <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName>
                <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055139" MajorTopicYN="N">Sensory Gating</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19020413</ArticleId>
            <ArticleId IdType="doi">10.1097/FBP.0b013e32831c3b2b</ArticleId>
            <ArticleId IdType="pii">00008877-200812000-00004</ArticleId>
            <ArticleId IdType="pmc">PMC3255557</ArticleId>
            <ArticleId IdType="mid">NIHMS89861</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Behav Brain Res. 2007 Aug 22;182(1):1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17570538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2007 Aug;193(2):159-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17393143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Psychiatry. 2008 Apr 15;63(8):748-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18083141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 2000 Apr 7;394(1):47-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10771033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2000 Jun;293(3):1048-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10869410</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Psychiatry. 2000 Oct;157(10):1660-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11007721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11549216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11549223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11549226</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):219-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11701191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2002 Nov;303(2):791-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12388666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Pharm Des. 2003;9(8):643-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12570797</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2003 Apr;28(4):640-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12655308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12668349</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neurochem. 2003 Nov;87(3):631-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14535946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2004 Feb;308(2):487-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14593083</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2004 Feb;77(2):291-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14751457</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2004 Aug;174(4):441-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15300358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2004 Aug;174(4):452-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15300359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 1975 May;12(3):238-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1153628</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 1978 Jul;15(4):339-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">693742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Psychiatry. 1986 Jan;21(1):23-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3080033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 1988;94(4):507-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3131796</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 1990 Jun;3(3):211-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2141986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1990 Sep 13;347(6289):146-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1975644</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 1994 Oct 3;263(3):235-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7843260</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 1995 Apr;12(2):139-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7779242</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Psychiatry. 1996 Jan 1;39(1):33-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8719124</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 1996 Sep 19;312(1):35-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8891576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Pharmacol. 1998 Sep;9(5-6):389-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9832924</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Pharmacol. 1998 Sep;9(5-6):445-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9832930</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Psychiatry. 2005 Jan;10(1):40-68; image 5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15263907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Discov Today. 2005 Jul 1;10(13):917-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15993811</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2005 Jul;2(7):e212</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16033310</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 2005 Sep;42(5):588-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16176381</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2006 Apr;31(4):721-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16123742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16613552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Brain Res. 2006 Nov 13;1119(1):203-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16979142</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Schizophr Bull. 2007 Jan;33(1):69-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17135482</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2007 May;87(1):1-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17475315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2008 Jan;88(3):306-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17900675</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
